Astex Drug Candidates to be Featured at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics



    CAMBRIDGE, England, Oct. 18 /CNW/ - Astex Therapeutics Ltd. today
announced that data on two of its drug candidates, AT7519 and AT13148, will be
presented at the 2007 AACR-NCI-EORTC International Conference on Molecular
Targets and Cancer Therapeutics, to be held October 22-26, 2007 in San
Francisco.
    AT7519 is a potent and selective Cyclin Dependent Kinase (CDK) inhibitor
currently in multi-centre Phase 1 clinical trials. AT13148 is a potent and
selective inhibitor of AKT and certain other AGC kinases, which is in
pre-clinical development.
    AT7519 and AT13148 are among five compounds currently being developed by
Astex for the treatment of solid tumours and haematological malignancies. All
of the compounds were discovered by Astex using its proprietary fragment-based
drug discovery platform Pyramid(TM).
    "With fewer than 100 people engaged in drug discovery and development at
Astex, we have generated a development pipeline of five novel products in less
than five years and put two of those products into clinical trials," said
Leon Bushara, Chief Executive of Astex. "That record of productivity is a
testament to the power of our drug discovery technology, the strength and
focus of our organisation, and the ingenuity of our scientists. Going forward,
we expect to introduce at least one new product into development every year."

    
    In addition to AT7519 and AT13148, Astex is developing:

    -   AT9283, a multi-targeted inhibitor of Aurora kinases, JAK2 and
        BCR-Abl, currently in multiple Phase 1 and Phase 1/2 multi-center
        clinical trials;

    -   AT13387, a selective inhibitor of Hsp90, for which Astex will file,
        during the fourth quarter of 2007, an Investigational New Drug (IND)
        application with the FDA to start clinical trials; and

    -   AT9311, a selective, orally administered, inhibitor of CDKs,
        partnered with Novartis.
    

    Astex also has five internal drug discovery programmes and is pursuing
another six projects in partnership with leading pharmaceutical companies
including Novartis, AstraZeneca, Bayer Schering and Boehringer Ingelheim.

    Poster Presentations at AACR-NCI-EORTC International Conference on
    Molecular Targets and Cancer Therapeutics

    Poster Title: A comparison of the pharmacological profile of AT7519 in
solid tumor and hematological cell lines.

    
    -------------------------------------------------------------------------
    Session Date :      Tuesday, October 23, 2007, 12:30 PM

    Session Title :     Poster Session A

    Session Subtitle :  Small Molecule Therapeutic Agents: Kinase Inhibitors

    Session Time :      12:30-2:30 PM and 5:30-7:30 PM

    Session Location :  Exhibit Hall, First Floor, Moscone Convention
                        Center West

    Abstract Number :   A247
    -------------------------------------------------------------------------

    Poster Title: AT13148, an orally bioavailable AKT kinase inhibitor with
potent anti-tumor activity in both in vitro and in vivo models exhibiting AKT
pathway deregulation.

    -------------------------------------------------------------------------
    Session Date :      Wednesday, October 24, 2007, 12:30 PM

    Session Title :     Poster Session B

    Session Subtitle :  Small Molecule Therapeutic Agents: Kinase Inhibitors

    Session Time :      12:30-2:30 PM and 5:30-7:30 PM

    Session Location :  Exhibit Hall, First Floor, Moscone Convention
                        Center West

    Abstract Number :   B251
    -------------------------------------------------------------------------
    

    About Astex

    Astex Therapeutics is a biotechnology company that discovers and develops
novel small molecule therapeutics. Using its pioneering fragment-based drug
discovery platform Pyramid(TM), Astex has built a pipeline of five
molecularly-targeted oncology drugs, of which two are currently being tested
in clinical trials and three are in pre-clinical development.
    In addition to its proprietary research programmes, Astex's unprecedented
productivity in lead discovery has been endorsed through numerous partnerships
with major pharmaceutical companies, including Novartis, AstraZeneca, and
Boehringer Ingelheim.
    For further information on Astex Therapeutics please visit the Company's
website at http://www.astex-therapeutics.com

    Web: http://www.astex-therapeutics.com





For further information:

For further information: Astex Therapeutics Limited, Jeremy Carmichael,
Director of Business Development, Email: j.carmichael@astex-therapeutics.com,
Tel: +44-(0)1223-226-200

Organization Profile

ASTEX THERAPEUTICS

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890